These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 17028572

  • 21. Sublingual apomorphine (Kynmobi) for Parkinson's disease.
    Med Lett Drugs Ther; 2020 Oct 19; 62(1609):165-166. PubMed ID: 33429410
    [No Abstract] [Full Text] [Related]

  • 22. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A, Turner K, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1998 May 19; 64(5):573-6. PubMed ID: 9598668
    [Abstract] [Full Text] [Related]

  • 23. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
    Pietz K, Hagell P, Odin P.
    J Neurol Neurosurg Psychiatry; 1998 Nov 19; 65(5):709-16. PubMed ID: 9810943
    [Abstract] [Full Text] [Related]

  • 24. [Practical use of continuous apomorphine infusion via pump].
    Tönges L, Ceballos-Baumann A, Honig H, Storch A, Jost WH.
    Fortschr Neurol Psychiatr; 2017 Sep 19; 85(9):516-535. PubMed ID: 28817841
    [Abstract] [Full Text] [Related]

  • 25. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D, Macías M, Llaneza M, Fuster-Sanjurjo L, Echarri-Piudo A, Belmonte S, Blanco S.
    Neurologia; 2010 Sep 19; 25(9):536-43. PubMed ID: 21093702
    [Abstract] [Full Text] [Related]

  • 26. [Device-aided therapies in advanced Parkinson's disease].
    Timofeeva AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016 Sep 19; 116(12):54-60. PubMed ID: 28139627
    [Abstract] [Full Text] [Related]

  • 27. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P, Kubová D, Bareš M, Hortová H, Streitová H, Rektor I, Znojil V.
    Mov Disord; 2002 Jan 19; 17(1):188-91. PubMed ID: 11835461
    [Abstract] [Full Text] [Related]

  • 28. [Limits of conventional oral and transdermal medication in Parkinson's disease].
    García-Ruiz PJ, Luquin MR.
    Rev Neurol; 2012 Jan 19; 55 Suppl 1():S3-6. PubMed ID: 23169231
    [Abstract] [Full Text] [Related]

  • 29. Practical use of apomorphine infusion in Parkinson's disease: lessons from the TOLEDO study and clinical experience.
    Henriksen T, Katzenschlager R, Bhidayasiri R, Staines H, Lockhart D, Lees A.
    J Neural Transm (Vienna); 2023 Nov 19; 130(11):1475-1484. PubMed ID: 37658155
    [Abstract] [Full Text] [Related]

  • 30. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.
    Grandas F.
    Expert Rev Neurother; 2013 Dec 19; 13(12):1343-53. PubMed ID: 24160681
    [Abstract] [Full Text] [Related]

  • 31. Apomorphine in the treatment of Parkinson's disease.
    Hagell P, Odin P.
    J Neurosci Nurs; 2001 Feb 19; 33(1):21-34, 37-8. PubMed ID: 11233359
    [Abstract] [Full Text] [Related]

  • 32. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
    Titova NV, Katunina EA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013 Feb 19; 113(12):105-12. PubMed ID: 24596973
    [No Abstract] [Full Text] [Related]

  • 33. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
    Henriksen T.
    Neurodegener Dis Manag; 2014 Feb 19; 4(3):271-82. PubMed ID: 25095821
    [Abstract] [Full Text] [Related]

  • 34. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E, Trzciniecka O, Rejdak K.
    Ann Agric Environ Med; 2019 Mar 22; 26(1):133-137. PubMed ID: 30922043
    [Abstract] [Full Text] [Related]

  • 35. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK, Bösch S, Luginger E, Wagner M, Poewe W.
    Adv Neurol; 1999 Mar 22; 80():545-8. PubMed ID: 10410769
    [No Abstract] [Full Text] [Related]

  • 36. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J, Merims D, Kuritzky A, Ziv I, Melamed E.
    Harefuah; 1999 Nov 15; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [Abstract] [Full Text] [Related]

  • 37. Apomorphine in the treatment of Parkinson's disease: a review.
    Pessoa RR, Moro A, Munhoz RP, Teive HAG, Lees AJ.
    Arq Neuropsiquiatr; 2018 Dec 15; 76(12):840-848. PubMed ID: 30698208
    [Abstract] [Full Text] [Related]

  • 38. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C, Zangger I, Fischer G.
    Schweiz Rundsch Med Prax; 1992 Aug 25; 81(35):1011-5. PubMed ID: 1410978
    [Abstract] [Full Text] [Related]

  • 39. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
    Salazar G, Martín J, Fragoso M, Font MA.
    Neurologia; 2017 Aug 25; 32(6):407-410. PubMed ID: 26699210
    [No Abstract] [Full Text] [Related]

  • 40. [Nocturnal continuous subcutaneous infusion of apomorphine in advanced Parkinson's disease: a series of 37 cases].
    García-Fernández C, Vargas-Mendoza AK, López-López B, Blázquez-Estrada M, Suárez-San Martín ME.
    Rev Neurol; 2024 Oct 16; 79(8):217-221. PubMed ID: 39404035
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.